How much funding has GeneDx raised?

GeneDx has raised $1.0B in total funding, most recently a Corporate Round.

Who are GeneDx's investors?

GeneDx's investors include Blackstone, BlackRock, Section 32, Oak HC/FT.

Where is GeneDx headquartered?

GeneDx is headquartered in Stamford.

What industry is GeneDx in?

GeneDx operates in Biotech, Healthcare, enterprise software.

GeneDx

IPO

Empowering everyone to live their healthiest life through genomics

Public · Stamford · Founded 2000 · $1.0B raised

Biotech

Healthcare

enterprise software

Headquarters: Stamford
Employees: 501–1000
Founded: 2000
Business Model: B2B
Website: genedx.com

Total Funding: $1.0B
Last Round: $200.0M Corporate RoundJan 2022
Rounds: 3
Type: Public

About

GeneDx is a genomics company that provides comprehensive genetic testing for rare and undiagnosed conditions. Founded in 2000 by NIH scientists, GeneDx offers whole exome sequencing, whole genome sequencing, and targeted genetic panels to clinicians and patients worldwide. The company has diagnosed over 4,800 genetic diseases and published over 1,000 scientific papers. GeneDx trades on Nasdaq under the ticker WGS and is headquartered in Stamford, Connecticut.

Summary

GeneDx is a Biotech company based in Stamford, founded in 2000. It has raised $1.0B in total across 3 rounds, most recently a $200.0M Corporate Round round in Jan 2022. Investors include Blackstone, BlackRock and Section 32.